$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000112623422000021 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$220.0K	$230.0K	$0.00
YoY Change		36.9%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.428M	$15.33M	$4.600M
YoY Change	-25.48%	-11.38%	318.18%
% of Gross Profit
Research & Development	$3.361M	$16.25M	$2.500M
YoY Change	34.44%	76.47%	4.17%
% of Gross Profit
Depreciation & Amortization	$10.00K	$273.0K	$200.0K
YoY Change	-95.0%	-53.25%	-87.5%
% of Gross Profit
Operating Expenses	$6.789M	$31.58M	$7.100M
YoY Change	-4.38%	19.29%	102.86%
Operating Profit		-$31.35M
YoY Change		19.18%
Interest Expense	$42.00K	$12.00K	$0.00
YoY Change		-94.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$250.0K	$281.0K	$0.00
YoY Change		-95.79%
Pretax Income	-$6.277M	-$31.07M	-$7.100M
YoY Change	-11.59%	58.21%	-14.46%
Income Tax	-$636.0K	-$636.0K	-$14.00M
% Of Pretax Income
Net Earnings	-$5.641M	-$30.43M	-$2.400M
YoY Change	135.04%	437.35%	-70.98%
Net Earnings / Revenue	-2564.09%	-13230.43%
Basic Earnings Per Share		-$3.65
Diluted Earnings Per Share	-$676.5K	-$3.65	-$289.2K
COMMON SHARES
Basic Shares Outstanding	8.357M shares	8.335M shares	8.297M shares
Diluted Shares Outstanding		8.335M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.81M	$94.81M	$98.70M
YoY Change	-3.94%	-3.94%	1874.0%
Cash & Equivalents	$94.81M	$94.81M	$98.70M
Short-Term Investments
Other Short-Term Assets	$4.740M	$4.740M	$3.500M
YoY Change	35.43%	35.43%	3400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$0.00		$26.15M
Total Short-Term Assets	$99.68M	$99.68M	$128.4M
YoY Change	-22.4%	-22.37%	2434.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$79.00K	$635.0K	$335.0K
YoY Change	-76.42%	5.83%	298.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$635.0K	$635.0K	$584.0K
YoY Change	8.73%	5.83%	27.79%
TOTAL ASSETS
Total Short-Term Assets	$99.68M	$99.68M	$128.4M
Total Long-Term Assets	$635.0K	$635.0K	$584.0K
Total Assets	$100.3M	$100.3M	$129.0M
YoY Change	-22.26%	-22.24%	2235.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$612.0K	$612.0K	$244.0K
YoY Change	150.82%	206.0%	-33.15%
Accrued Expenses	$4.166M	$4.518M	$5.898M
YoY Change	-29.37%	-27.13%	731.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.130M	$5.130M	$6.461M
YoY Change	-20.6%	-21.08%	411.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.205M	$6.205M	$6.000M
YoY Change	3.42%	3.42%	2900.0%
Total Long-Term Liabilities	$6.205M	$6.205M	$6.000M
YoY Change	3.42%	3.42%	3041.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.130M	$5.130M	$6.461M
Total Long-Term Liabilities	$6.205M	$6.205M	$6.000M
Total Liabilities	$11.34M	$11.34M	$12.46M
YoY Change	-9.04%	-9.32%	757.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$96.42M		-$65.99M
YoY Change	46.11%		10.58%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$114.0K		$0.00
YoY Change
Treasury Stock Shares	9.428K shares		0.000 shares
Shareholders Equity	$88.98M	$88.98M	$116.6M
YoY Change
Total Liabilities & Shareholders Equity	$100.3M	$100.3M	$129.0M
YoY Change	-22.26%	-22.24%	2235.02%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$5.641M	-$30.43M	-$2.400M
YoY Change	135.04%	437.35%	-70.98%
Depreciation, Depletion And Amortization	$10.00K	$273.0K	$200.0K
YoY Change	-95.0%	-53.25%	-87.5%
Cash From Operating Activities	-$5.828M	-$29.65M	-$7.000M
YoY Change	-16.74%	28.92%	-70.59%
INVESTING ACTIVITIES
Capital Expenditures	-$13.00K	-$30.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$26.00M	$0.00
YoY Change		-77.72%	-100.0%
Cash From Investing Activities	-$13.00K	$25.97M	-$100.0K
YoY Change	-87.0%	-77.74%	-200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.000K
YoY Change		-75.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-$192.0K	100.0K
YoY Change	-100.0%	-356.0%	-200.0%
NET CHANGE
Cash From Operating Activities	-5.828M	-$29.65M	-7.000M
Cash From Investing Activities	-13.00K	$25.97M	-100.0K
Cash From Financing Activities	0.000	-$192.0K	100.0K
Net Change In Cash	-5.841M	-$3.870M	-7.000M
YoY Change	-16.56%	-104.13%	-70.59%
FREE CASH FLOW
Cash From Operating Activities	-$5.828M	-$29.65M	-$7.000M
Capital Expenditures	-$13.00K	-$30.00K	$0.00
Free Cash Flow	-$5.815M	-$29.62M	-$7.000M
YoY Change	-16.93%	28.79%	-70.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1111
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35342
CY2021	dei	Entity Registrant Name EntityRegistrantName	LUMOS PHARMA, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	42-1491350
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	4200 Marathon Blvd #200
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78756
CY2021	dei	City Area Code CityAreaCode	512
CY2021	dei	Local Phone Number LocalPhoneNumber	215-2630
CY2021	dei	Security12b Title Security12bTitle	Common Stock
CY2021	dei	Trading Symbol TradingSymbol	LUMO
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	63200000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8358625	shares
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	Austin, TX
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94809000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98679000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4740000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3506000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	128000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	115000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	26149000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	99677000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	128449000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	335000	USD
CY2021Q4	nlnk	Operating Lease Rightof Use Asset Noncurrent OperatingLeaseRightofUseAssetNoncurrent	556000	USD
CY2020Q4	nlnk	Operating Lease Rightof Use Asset Noncurrent OperatingLeaseRightofUseAssetNoncurrent	249000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	635000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	584000	USD
CY2021Q4	us-gaap	Assets Assets	100312000	USD
CY2020Q4	us-gaap	Assets Assets	129033000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	612000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	244000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4166000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5898000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	352000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	319000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5130000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6461000	USD
CY2021Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2020Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	205000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6205000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6000000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	11335000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	12461000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8366819	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8305269	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8357391	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8305269	shares
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	83000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	83000	USD
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	9428	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	114000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	185429000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	182480000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96421000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65991000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	88977000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	116572000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100312000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	129033000	USD
CY2021	us-gaap	Revenues Revenues	230000	USD
CY2020	us-gaap	Revenues Revenues	168000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16246000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9206000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15331000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17265000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	31577000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	26471000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-31347000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-26303000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	269000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6467000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	200000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	281000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6667000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31066000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19636000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-636000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13973000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30430000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2021	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2020	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	651000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30430000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6314000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.65
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.65
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8334516	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8334516	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6777932	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6777932	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-59463000	USD
CY2020	nlnk	Preferred Stock Accretion Of Preferred Dividend Prior To Acquisition PreferredStockAccretionOfPreferredDividendPriorToAcquisition	651000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	116949000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	64186000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1074000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	116000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	24000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	116572000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2879000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	64000	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	114000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	6000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30430000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	88977000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30430000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2879000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1074000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	273000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	584000	USD
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	USD
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	6300000	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-14000	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2021	nlnk	Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability	70000	USD
CY2020	nlnk	Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability	0	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	426000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9500000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1086000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	731000	USD
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-136000	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-309000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1364000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3196000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29648000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22997000	USD
CY2021	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	USD
CY2020	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	84179000	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	26000000	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	32500000	USD
CY2021	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	30000	USD
CY2020	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	30000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25970000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	116649000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	64000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	116000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	114000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	148000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	38000	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	27000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-192000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3870000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	93727000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98679000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94809000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98679000	USD
CY2021	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2020	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	4473000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8000	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	64186000	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	116949000	USD
CY2021	nlnk	Settlement Of Liability Related To Priority Review Voucher SettlementOfLiabilityRelatedToPriorityReviewVoucher	0	USD
CY2020	nlnk	Settlement Of Liability Related To Priority Review Voucher SettlementOfLiabilityRelatedToPriorityReviewVoucher	35720000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Organization and Nature of operations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this Annual Report to “us,” “we,” “our,” the “Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing our clinical program and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">focused on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identifying, acquiring, developing, and commercializing novel products and new therapies for people with rare diseases on a global level</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which there is currently a significant unmet need for safe and effective therapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) and trades under</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the ticker symbol “LUMO.”</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a business combination (the “Merger”) between</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger closed on March 18, 2020, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Merger, the shares of NewLink common stock were adjusted with a reverse split ratio of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1‑for‑9.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of the Merger, Private Lumos stockholders received an aggregate of 4,146,398 shares </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of NewLink common stock (after giving effect to the reverse split)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each share of outstanding common stock, Series A Preferred Stock and Series B Preferred Stock of Private Lumos converted at an exchange ratio of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1308319305, 0.0873621142 and 0.1996348626</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Immediately following the reverse stock split and the completion of the Merger, there were 8,292,803 shares of the Company’s common stock outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of which approximately 50% was held by each of Private Lumos and NewLink security holders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse asset acquisition. Private Lumos was deemed to be the accounting acquirer for accounting purposes and NewLink </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> accounting acquiree. Accordingly, for accounting purposes: (i) the assets acquired and liabilities assumed were recorded based on their estimated fair values on the Merger date,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the reported historical operating results of the combined company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Merger will be those of Private Lumos and not of NewLink after retroactively giving effect to the common stock exchange ratio, reverse stock split and change in par value for all periods presented, and (iii) for periods prior to the transaction, shareholders’ authorized capital of the combined company is presented based on the historical authorized capital of NewLink.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the consummation of the Merger, the combined company has focused its efforts on the development of Private Lumos’ sole product candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secretagogue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ibutamoren (“LUM-201”), a potential oral therapy for pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. However, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company believes that its existing cash and cash equivalents </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of approximat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely $94.8 million as of December 31, 2021 will be sufficient to allow the Company to fund its operations through the primary read out of the OraGrowtH210 and OraGrowtH212 Trials for a subset of patients with PGHD and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for at least 12 months from the filing date of this Annual Report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If available liquidity becomes insufficient to meet the Company’s obligations as they come due, our f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uture operations will be reliant on additional equity or financing arrangements. There can be no assurances that, in the event that the Company requires additional financing, such financing will be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic caused by an outbreak of a novel strain of coronavirus, SARS-CoV-2, which causes COVID-19 (“COVID-19”), has resulted, and is likely to continue to result, in significant national and global economic disruption and may continue to adversely affect the Company’s operations. COVID-19 restrictions have led to a slower pace of site initiation and patient enrollment in our clinical trials that has delayed the 6-month primary outcome data read out of our OraGrowth210 Trial. </span></div>While we have experienced delays to our clinical trials, we have not incurred impairment of any assets as a result of COVID-19. The extent to which these events may further impact the Company’s business, clinical development, regulatory efforts, and the value of its common stock, will depend on future developments, which are highly uncertain and cannot be predicted at this time. The duration and intensity of these impacts and resulting disruption to the Company’s operations is uncertain and the Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8292803	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94800000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include stock-based compensation, accruals for clinical trials and deferred tax assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that the estimates and assumptions used in preparation of our consolidated financial statements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on our knowledge of current events and actions that we may undertake in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are appropriate, actual results could differ from those estimates, and any such differences may be material.</span></div>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94800000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98700000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2800000	USD
CY2021Q4	nlnk	Accrued Clinical Expenses AccruedClinicalExpenses	500000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	900000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	3300000	USD
CY2020Q4	nlnk	Accrued Clinical Expenses AccruedClinicalExpenses	200000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2400000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds.
CY2020Q1	nlnk	Number Of Board Of Directors NumberOfBoardOfDirectors	3	director
CY2021	us-gaap	Payments For Royalties PaymentsForRoyalties	146000	USD
CY2020	us-gaap	Payments For Royalties PaymentsForRoyalties	0	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.03
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	337000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	236000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	573000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	557000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	337000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	371000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2879000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1074000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4500000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-600000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14000000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-4473000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-636000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7980000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1520000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-636000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13973000	USD
CY2021Q4	nlnk	Cares Act Operating Loss Carry Back Before Tax CARESActOperatingLossCarryBackBeforeTax	4500000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	9500000	USD
CY2021Q4	nlnk	Cares Act Operating Loss Carry Back Before Tax CARESActOperatingLossCarryBackBeforeTax	4500000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32281000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27441000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	37953000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	34238000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	627000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	624000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	41144000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	41399000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	2000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	109000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	192000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	361000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	24000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	25000	USD
CY2021Q4	nlnk	Deferred Tax Assets Leasehold Improvements And Equipment DeferredTaxAssetsLeaseholdImprovementsAndEquipment	1292000	USD
CY2020Q4	nlnk	Deferred Tax Assets Leasehold Improvements And Equipment DeferredTaxAssetsLeaseholdImprovementsAndEquipment	1648000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	113515000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105845000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	113515000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105272000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	573000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	573000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8200000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	95700000	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	127500000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0138
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.5050
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	1.7731
CY2021	nlnk	Effective Income Tax Rate Reconciliation Federal Operating Loss Carryback EffectiveIncomeTaxRateReconciliationFederalOperatingLossCarryback	0
CY2020	nlnk	Effective Income Tax Rate Reconciliation Federal Operating Loss Carryback EffectiveIncomeTaxRateReconciliationFederalOperatingLossCarryback	0.2278
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0890
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0357
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2653
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.0118
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0270
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0282
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0205
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.7116
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	700000	USD
CY2021Q4	nlnk	Liability For Uncertainty In Income Taxes Current Period Increase Decrease LiabilityForUncertaintyInIncomeTaxesCurrentPeriodIncreaseDecrease	-1200000	USD
CY2021Q4	nlnk	Common Stock Number Of Votes Each Share Is Entitled To CommonStockNumberOfVotesEachShareIsEntitledTo	1	vote
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	nlnk	Common Stock Number Of Votes Each Share Is Entitled To CommonStockNumberOfVotesEachShareIsEntitledTo	1	vote
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30430000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2021	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2020	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	651000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30430000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6314000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8334516	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8334516	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6777932	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6777932	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.65
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.65
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1282224	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1032699	shares
CY2021Q2	nlnk	Deferred Compensation Arrangement With Individual Accelerated Vesting Expense DeferredCompensationArrangementWithIndividualAcceleratedVestingExpense	700000	USD

Files In Submission

Name	View Source	Status
0001126234-22-000021-index-headers.html	Edgar Link	pending
0001126234-22-000021-index.html	Edgar Link	pending
0001126234-22-000021.txt	Edgar Link	pending
0001126234-22-000021-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lumo-20211231x10kxex311.htm	Edgar Link	pending
lumo-20211231x10kxex312.htm	Edgar Link	pending
lumo-20211231x10kxex321.htm	Edgar Link	pending
lumo-20211231x10xkxex1020.htm	Edgar Link	pending
lumo-20211231x10xkxex211.htm	Edgar Link	pending
lumo-20211231x10xkxex231.htm	Edgar Link	pending
lumo-20211231x10xkxex31.htm	Edgar Link	pending
lumo-20211231x10xkxex42.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nlnk-20211231.htm	Edgar Link	pending
nlnk-20211231.xsd	Edgar Link	pending
nlnk-20211231_cal.xml	Edgar Link	unprocessable
nlnk-20211231_def.xml	Edgar Link	unprocessable
nlnk-20211231_g1.jpg	Edgar Link	pending
nlnk-20211231_g2.jpg	Edgar Link	pending
nlnk-20211231_g3.jpg	Edgar Link	pending
nlnk-20211231_g4.jpg	Edgar Link	pending
nlnk-20211231_htm.xml	Edgar Link	completed
nlnk-20211231_lab.xml	Edgar Link	unprocessable
nlnk-20211231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2021 Q4 Form 10-K Financial Statement

#000112623422000021 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2021 Q4 Form 10-K Financial Statement

#000112623422000021 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo